How the Neuropeptides VIP and PACAP Influence Migraines, PTSD, Addiction, and Autoimmune Diseases
The neuropeptides VIP and PACAP play key roles in migraines, PTSD, addiction, and autoimmune conditions like rheumatoid arthritis, with new antibody-based drugs now entering development to target this peptide system.
Quick Facts
What This Study Found
PACAP plays an important role in the pathogenesis of headaches (particularly migraine), post-traumatic stress disorder, and drug/alcohol/smoking addiction. VIP has demonstrated therapeutic effects in autoimmune and inflammatory disorders, especially rheumatoid arthritis. The development of specific drugs targeting this system — including monoclonal antibodies against VIP and PACAP — has advanced to therapeutic trials in some cases.
Key Numbers
PACAP: migraine, PTSD, addiction; VIP: rheumatoid arthritis; new: anti-VIP/PACAP monoclonal antibodies in development
How They Did This
This is a narrative review (Part 2 of a series) discussing recent advances in understanding VIP/PACAP receptor biology in central nervous system and inflammatory disorders. The authors synthesize findings from basic science and clinical research on these neuropeptides.
Why This Research Matters
The success of CGRP-targeting antibodies for migraine proved that neuropeptide-based therapies can transform treatment of neurological conditions. VIP and PACAP represent the next frontier — a related neuropeptide system that appears to be involved not just in migraine but also in PTSD, addiction, and autoimmune diseases. If anti-VIP/PACAP drugs follow the trajectory of anti-CGRP drugs, they could provide new treatment options for millions of patients with these difficult-to-treat conditions.
The Bigger Picture
Neuropeptides are emerging as major drug targets across neurology, psychiatry, and immunology. After the breakthrough success of anti-CGRP antibodies for migraine, the VIP/PACAP system is the next neuropeptide pathway attracting pharmaceutical investment. The fact that these two peptides span both brain disorders and autoimmune conditions reflects the deep connection between the nervous and immune systems — a frontier that peptide therapeutics are uniquely positioned to exploit.
What This Study Doesn't Tell Us
This is a narrative review, not a systematic review or meta-analysis, so the evidence selection may not be comprehensive. Many of the associations described are at the basic science level, and clinical trial data for anti-PACAP drugs remain limited. The mechanisms by which VIP/PACAP contribute to conditions like PTSD and addiction are not yet fully understood. The review does not provide quantitative outcome data.
Questions This Raises
- ?Will anti-PACAP antibodies prove as effective for migraine prevention as anti-CGRP antibodies, and could they help CGRP non-responders?
- ?Could VIP-based therapies offer a new approach to rheumatoid arthritis for patients who don't respond to current biologics?
- ?How do the VIP/PACAP and CGRP neuropeptide systems interact in migraine pathophysiology?
Trust & Context
- Key Stat:
- New monoclonal antibodies in development Anti-VIP/PACAP antibodies are following the path of successful anti-CGRP migraine drugs, now targeting a neuropeptide system implicated in migraine, PTSD, addiction, and rheumatoid arthritis
- Evidence Grade:
- This is a narrative review article summarizing recent advances in the field. It provides expert synthesis of current knowledge but does not present new data. The evidence base ranges from strong (PACAP's role in migraine) to preliminary (roles in PTSD and addiction).
- Study Age:
- Published in 2021, this review covers research advances up to that point. The VIP/PACAP field has continued to develop since then, with anti-PACAP therapies progressing further in clinical trials.
- Original Title:
- Pituitary adenylate cyclase-activating polypeptide/vasoactive intestinal peptide (Part 2): biology and clinical importance in central nervous system and inflammatory disorders.
- Published In:
- Current opinion in endocrinology, diabetes, and obesity, 28(2), 206-213 (2021)
- Authors:
- Moody, Terry W(2), Jensen, Robert T(2)
- Database ID:
- RPEP-05626
Evidence Hierarchy
Summarizes existing research on a topic.
What do these levels mean? →Frequently Asked Questions
What are VIP and PACAP, and what do they do in the body?
VIP (vasoactive intestinal peptide) and PACAP (pituitary adenylate cyclase-activating polypeptide) are naturally occurring signaling peptides found throughout the body, especially in the brain and immune system. They regulate blood vessel dilation, inflammation, pain signaling, stress responses, and immune cell activity. When their signaling goes wrong, it can contribute to migraines, stress disorders, and autoimmune inflammation.
How are these peptides connected to both migraines and autoimmune diseases?
VIP and PACAP bridge the nervous and immune systems. PACAP is released by nerves during migraine attacks and triggers blood vessel dilation and pain. VIP modulates immune cell behavior and inflammation. Because these peptides work at the nerve-immune interface, targeting them could treat neurological conditions (like migraine and PTSD) and autoimmune conditions (like rheumatoid arthritis) through the same receptor system.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-05626APA
Moody, Terry W; Jensen, Robert T. (2021). Pituitary adenylate cyclase-activating polypeptide/vasoactive intestinal peptide (Part 2): biology and clinical importance in central nervous system and inflammatory disorders.. Current opinion in endocrinology, diabetes, and obesity, 28(2), 206-213. https://doi.org/10.1097/MED.0000000000000621
MLA
Moody, Terry W, et al. "Pituitary adenylate cyclase-activating polypeptide/vasoactive intestinal peptide (Part 2): biology and clinical importance in central nervous system and inflammatory disorders.." Current opinion in endocrinology, 2021. https://doi.org/10.1097/MED.0000000000000621
RethinkPeptides
RethinkPeptides Research Database. "Pituitary adenylate cyclase-activating polypeptide/vasoactiv..." RPEP-05626. Retrieved from https://rethinkpeptides.com/research/moody-2021-pituitary-adenylate-cyclaseactivating-polypeptidevasoactive
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.